Regulatory B cells in autoimmune diseases

Cellular and Molecular Immunology

Volumn 10, Issue 2, 2013, Pages 122-132

  Yang, Min ^a   Rui, Ke ^b   Wang, Shengjun ^b   Lu, Liwei ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b JIANGSU UNIVERSITY   (China)

Author keywords

autoimmune disease; interleukin 10; regulatory B cells

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA;

ALLERGIC ENCEPHALOMYELITIS; ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE IDENTIFICATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR PARAMETERS; CYTOKINE PRODUCTION; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; INTRACELLULAR SIGNALING; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOIMMUNE DISEASES; B-LYMPHOCYTE SUBSETS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOPHENOTYPING; INFLAMMATION; INTERLEUKIN-10; MICE; TRANSFORMING GROWTH FACTOR BETA;

EID: 84874617591     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2012.60     Document Type: Review

References (116)

1. Osmond DG. B cell development in the bone marrow. Semin Immunol 1990; 2: 173-180.
2. Cooper MD. Exploring lymphocyte differentiation pathways. Immunol Rev 2002; 185: 175-185.
3. Welner RS, Pelayo R, Kincade PW. Evolving views on the genealogy of B cells. Nat Rev Immunol 2008; 8: 95-106.
4. Katz SI, Parker D, Turk JL. B-cell suppression of delayed hypersensitivity reactions. Nature 1974; 251: 550-551.
5. Neta R, Salvin SB. Specific suppression of delayed hypersensitivity: the possible presence of a suppressor B cell in the regulation of delayed hypersensitivity. J Immunol 1974; 113: 1716-1725.
6. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol 2006; 176: 705-710.
7. Lundy SK. Killer B lymphocytes: the evidence and the potential. Inflamm Res 2009; 58: 345-357.
8. Gray D, Gray M. What are regulatory B cells? Eur J Immunol 2010; 40: 2677-2679.
9. DiLillo DJ, Matsushita T, Tedder TF. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann NY Acad Sci 2010; 1183: 38-57.
10. Blair PA, Norena LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR et al. CD191CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010; 32: 129-140.
11. Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, VenturiGMet al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011; 117: 530-541.
12. Wolf SD, Dittel BN, Hardardottir F, Janeway CA Jr. Experimental autoimmune encephalomyelitis induction in genetically B celldeficient mice. J Exp Med 1996; 184: 2271-2278.
13. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002; 3: 944-950.
14. Mizoguchi A, Mizoguchi E, Smith RN, Preffer FI, Bhan AK. Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med 1997; 186: 1749-1756.
15. Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002; 16: 219-230.
16. O'Garra A, Chang R, Go N, Hastings R, Haughton G, Howard M. Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. Eur J Immunol 1992; 22: 711-717.
17. Spencer NF, Daynes RA. IL-12 directly stimulates expression of IL-10 by CD51 B cells and IL-6 by both CD51 and CD52 B cells: possible involvement in age-associated cytokine dysregulation. Int Immunol 1997; 9: 745-754.
18. Lenert P, Brummel R, Field EH, Ashman RF. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J Clin Immunol 2005; 25: 29-40.
19. Evans JG, Chavez-Rueda KA, Eddaoudi A, Meyer-Bahlburg A, Rawlings DJ, Ehrenstein MR et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 2007; 178: 7868-7878.
20. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory Bcell subset with a unique CD1dhiCD51 phenotype controls T cell-dependent inflammatory responses. Immunity 2008; 28: 639-650.
21. Rafei M, Hsieh J, Zehntner S, Li M, Forner K, Birman E et al. A granulocyte-macrophage colony-stimulating factor and interleukin-fusokine induces a regulatory B cell population with immune suppressive properties. Nat Med 2009; 15: 1038-1045.
22. Ding Q, Yeung M, Camirand G, Zeng Q, Akiba H, Yagita H et al. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J Clin Invest 2011; 121: 3645-3656.
23. Qian L, Qian C, Chen Y, Bai Y, Bao Y, Lu L et al. Regulatory dendritic cells program B cells to differentiate into CD19hiFcgammaIIbhi regulatory B cells through IFN-beta and CD40L. Blood 2012; 120: 581-591.
24. Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007; 178: 6092-6099.
25. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 2004; 172: 3422-3427.
26. Edwards JC, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 1999; 97: 188-196.
27. Shimomura Y, Mizoguchi E, Sugimoto K, Kibe R, Benno Y, Mizoguchi A et al. Regulatory role of B-1 B cells in chronic colitis. Int Immunol 2008; 20: 729-737.
28. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001; 1: 147-153.
29. Rodriguez-Pinto D, Moreno J. B cells can prime naive CD41 T cells in vivo in the absence of other professional antigen-presenting cells in a CD1542CD40-dependent manner. Eur J Immunol 2005; 35: 1097-1105.
30. Yan J, Harvey BP, Gee RJ, Shlomchik MJ, Mamula MJ. B cells drive early T cell autoimmunity in vivo prior to dendritic cell-mediated autoantigen presentation. J Immunol 2006; 177: 4481-4487.
31. Fuchs EJ, Matzinger P. B cells turn off virgin but not memory T cells. Science 1992; 258: 1156-1159.
32. Eynon EE, Parker DC. Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med 1992; 175: 131-138.
33. Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000; 1: 475-482.
34. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996; 85: 307-310.
35. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376: 1094-1108.
36. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med 1977; 146: 857-868.
37. Lu L, Osmond DG. Apoptosis and its modulation during B lymphopoiesis in mouse bone marrow. Immunol Rev 2000; 175: 158-174.
38. Zhang M, Srivastava G, Lu L. The pre-B cell receptor and its function during B cell development. Cell Mol Immunol 2004; 1: 89-94.
39. Zhang M, Ko KH, Lam QL, Lo CK, Srivastava G, Zheng B et al. Expression and function of TNF family member B cell-activating factor in the development of autoimmune arthritis. Int Immunol 2005; 17: 1081-1092.
40. Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF. B-lymphocyte contributions to human autoimmune disease. Immunol Rev 2008; 223: 284-299.
41. Lo CK, Lam QL, Sun L, Wang S, Ko KH, Xu H et al. Natural killer cell degeneration exacerbates experimental arthritis in mice via enhanced interleukin-17 production. Arthritis Rheum 2008; 58: 2700-2711.
42. Yanaba K, Hamaguchi Y, Venturi GM, Steeber DA, St Clair EW, Tedder TF. B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J Immunol 2007; 179: 1369-1380.
43. Mauri C, Gray D, Mushtaq N, Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003; 197: 489-501.
44. Gray M, Miles K, Salter D, Gray D, Savill J. Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells. Proc Natl Acad Sci USA 2007; 104: 14080-14085.
45. Yang M, Deng J, Liu Y, Ko KH, Wang X, Jiao Z et al. IL-10-producing regulatory B10 cells ameliorate collagen-induced arthritis via suppressing Th17 cell generation. Am J Pathol 2012; 180: 2375-2385.
46. Yang M, Sun L, Wang S, Ko KH, Xu H, Zheng BJ et al. Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells. J Immunol 2010; 184: 3321-3325.
47. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005; 23: 447-485.
48. Silveira PA, Grey ST. B cells in the spotlight: innocent bystanders or major players in the pathogenesis of type 1 diabetes. Trends Endocrinol Metab 2006; 17: 128-135.
49. Fox CJ, Danska JS. Independent genetic regulation of T-cell and antigen-presenting cell participation in autoimmune islet inflammation. Diabetes 1998; 47: 331-338.
50. Kendall PL, Yu G, Woodward EJ, Thomas JW. Tertiary lymphoid structures in the pancreas promote selection of B lymphocytes in autoimmune diabetes. J Immunol 2007; 178: 5643-5651.
51. Henry RA, Kendall PL. CXCL13 blockade disrupts B lymphocyte organization in tertiary lymphoid structures without altering B cell receptor bias or preventing diabetes in nonobese diabetic mice. J Immunol 2010; 185: 1460-1465.
52. Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF. B-lymphocyte contributions to human autoimmune disease. Immunol Rev 2008; 223: 284-299.
53. Xiu Y, Wong CP, Bouaziz JD, Hamaguchi Y, Wang Y, Pop SM et al. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. J Immunol 2008; 180: 2863-2875.
54. Marino E, Villanueva J, Walters S, Liuwantara D, Mackay F, Grey ST. CD41CD251 T-cells control autoimmunity in the absence of B-cells. Diabetes 2009; 58: 1568-1577.
55. Smith SH, Tedder TF. Targeting B-cells mitigates autoimmune diabetes in NOD mice: what is plan B? Diabetes 2009; 58: 1479-1481.
56. Hussain S, Delovitch TL. Intravenous transfusion of BCR-activated B cells protects NOD mice from type 1 diabetes in an IL-10-dependent manner. J Immunol 2007; 179: 7225-7232.
57. Tian J, Zekzer D, Hanssen L, Lu Y, Olcott A, Kaufman DL. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J Immunol 2001; 167: 1081-1089.
58. Hussain S, Delovitch TL. Intravenous transfusion of BCR-activated B cells protects NOD mice from type 1 diabetes in an IL-10-dependent manner. J Immunol 2007; 179: 7225-7232.
59. Williams KC, Ulvestad E, Hickey WF. Immunology of multiple sclerosis. Clin Neurosci 1994; 2: 229-245.
60. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002; 3: 944-950.
61. Cross AH, Trotter JL, Lyons J. B cells and antibodies in CNS demyelinating disease. J Neuroimmunol 2001; 112: 1-14.
62. Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008; 224: 201-214.
63. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008; 118: 3420-3430.
64. Ray A, Mann MK, Basu S, Dittel BN. A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neuroimmunol 2011; 230: 1-9.
65. Matsushita T, Horikawa M, Iwata Y, Tedder TF. Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J Immunol 2010; 185: 2240-2252.
66. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001; 2: 764-766.
67. Grammer AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003; 112: 1506-1520.
68. Mountz J. Animal models of systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol 1990; 2: 740-748.
69. Wither JE, Roy V, Brennan LA. Activated B cells express increased levels of costimulatory molecules in young autoimmune NZB and (NZB3NZW)F1 mice. Clin Immunol 2000; 94: 51-63.
70. Schuster H, Martin T, Marcellin L, Garaud JC, Pasquali JL, Korganow AS. Expansion of marginal zone B cells is not sufficient for the development of renal disease in NZB3NZW F1 mice. Lupus 2002; 11: 277-286.
71. Atencio S, Amano H, Izui S, Kotzin BL. Separation of the New Zealand Black genetic contribution to lupus from New Zealand Black determined expansions of marginal zone B and B1a cells. J Immunol 2004; 172: 4159-4166.
72. Vyse TJ, Halterman RK, Rozzo SJ, Izui S, Kotzin BL. Control of separate pathogenic autoantibody responses marks MHC gene contributions to murine lupus. Proc Natl Acad Sci USA 1999; 96: 8098-8103.
73. Chan OT, Madaio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 1999; 169: 107-121.
74. Haas KM, Watanabe R, Matsushita T, Nakashima H, Ishiura N, Okochi H et al. Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice. J Immunol 2010; 184: 4789-4800.
75. Watanabe R, Ishiura N, Nakashima H, Kuwano Y, Okochi H, Tamaki K et al. Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol 2010; 184: 4801-4809.
76. Blair PA, Chavez-Rueda KA, Evans JG, Shlomchik MJ, Eddaoudi A, Isenberg DA et al. Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol 2009; 182: 3492-3502.
77. Palanichamy A, Barnard J, Zheng B, Owen T, Quach T, Wei C et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol 2009; 182: 5982-5993.
78. Plebani A, Lougaris V, Soresina A, Meini A, Zunino F, Losi CG et al. A novel immunodeficiency characterized by the exclusive presence of transitional B cells unresponsive to CpG. Immunology 2007; 121: 183-188.
79. Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007; 56: 3044-3056.
80. Sanz I, Wei C, Lee FE, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 2008; 20: 67-82.
81. Agematsu K, Hokibara S, Nagumo H, Komiyama A. CD27: a memory B-cell marker. Immunol Today 2000; 21: 204-206.
82. Bouaziz JD, Calbo S, Maho-Vaillant M, Saussine A, Bagot M, Bensussan A et al. IL-10 produced by activated human B cells regulates CD41 T-cell activation in vitro. Eur J Immunol 2010; 40: 2686-2691.
83. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001; 40: 205-211.
84. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581.
85. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613-620.
86. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688.
87. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589.
88. Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 2007; 13: 1365-1368.
89. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007; 56: 2715-2718.
90. Lampropoulou V, Hoehlig K, Roch T, Neves P, Calderon Gomez E, Sweenie CH et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J Immunol 2008; 180: 4763-4773.
91. Yanaba K, Bouaziz JD, Matsushita T, Tsubata T, Tedder TF. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol 2009; 182: 7459-7472.
92. Gary-Gouy H, Harriague J, Bismuth G, Platzer C, Schmitt C, Dalloul AH. Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood 2002; 100: 4537-4543.
93. Tu W, Lau YL, Zheng J, Liu Y, Chan PL, Mao H et al. Efficient generation of human alloantigen-specific CD41 regulatory T cells from naive precursors by CD40-activated B cells. Blood 2008; 112: 2554-2562.
94. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293: 2111-2114.
95. Schneider P, Takatsuka H, Wilson A, Mackay F, Tardivel A, Lens S et al. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med 2001; 194: 1691-1697.
96. Walters S, Webster KE, Sutherland A, Gardam S, Groom J, Liuwantara D et al. Increased CD41Foxp31 T cells in BAFF-transgenic mice suppress T cell effector responses. J Immunol 2009; 182: 793-801.
97. Gray M, Miles K, Salter D, Gray D, Savill J. Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells. Proc Natl Acad Sci USA 2007; 104: 14080-14085.
98. Lopes-Carvalho T, Kearney JF. Development and selection of marginal zone B cells. Immunol Rev 2004; 197: 192-205.
99. Evans JG, Chavez-Rueda KA, Eddaoudi A,Meyer-Bahlburg A, Rawlings DJ, Ehrenstein MR et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 2007; 178: 7868-7878.
100. Mauri C. Regulation of immunity and autoimmunity by B cells. Curr Opin Immunol 2010; 22: 761-767.
101. Carter NA, Vasconcellos R, Rosser EC, Tulone C, Munoz-Suano A, Kamanaka M et al. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol 2011; 186: 5569-5579.
102. Moulin V, Andris F, Thielemans K, Maliszewski C, Urbain J, Moser M. Blymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med 2000; 192: 475-482.
103. Tian J, Zekzer D, Hanssen L, Lu Y, Olcott A, Kaufman DL. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J Immunol 2001; 167: 1081-1089.
104. Parekh VV, Prasad DV, Banerjee PP, Joshi BN, Kumar A, Mishra GC. B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD81 T cells: role of TGF-beta 1. J Immunol 2003; 170: 5897-5911.
105. Tedder TF, Matsushit, T. Regulatory B cells that produce IL-10: a breath of fresh air in allergic airway disease. J Allergy Clin Immunol 2010; 125: 1125-1127.
106. Amu S, Saunders SP, Kronenberg M, Mangan NE, Atzberger A, Fallon PG. Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model. J Allergy Clin Immunol 2010; 125: 1114-1124.e8.
107. Carter NA, Rosser EC, Mauri C. IL-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of Tr1 cells and reduction of collagen-induced arthritis. Arthritis Res Ther 2012; 14: R32.
108. Bialecki E, Paget C, Fontaine J, Capron M, Trottein F, Faveeuw C. Role of marginal zone B lymphocytes in invariant NKT cell activation. J Immunol 2009; 182: 6105-6113.
109. Sonoda KH, Stein-Streilein J. CD1d on antigen-transporting APC and splenic marginal zone B cells promotes NKT cell-dependent tolerance. Eur J Immunol 2002; 32: 848-857.
110. Croxford JL, Miyake S, Huang YY, Shimamura M, Yamamura T. Invariant Valpha19i T cells regulate autoimmune inflammation. Nat Immunol 2006; 7: 987-994.
111. Bosma A, Abdel-Gadir A, Isenberg DA, Jury EC, Mauri C. Lipid-antigen presentation by CD1d1 B cells is essential for the maintenance of invariant natural killer T cells. Immunity 2012; 36: 477-490.
112. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007; 8: 239-245.
113. Alderson MR, Lynch DH. Receptors and ligands that mediate activation-induced death of T cells. Springer Semin Immunopathol 1998; 19: 289-300.
114. Anel A, Bosque A, Naval J, Pineiro A, Larrad L, AlavaMAet al. Apo2L/TRAIL and immune regulation. Front Biosci 2007; 12: 2074-2084.
115. Ray A, Basu S, Williams CB, Salzman NH, Dittel BN. A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand. J Immunol 2012; 188: 3188-3198.
116. Mann MK, Maresz K, Shriver LP, Tan Y, Dittel BN. B cell regulation of CD41CD251 T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J Immunol 2007; 178: 3447-3456.